Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

 in 2023, where she produces written content covering multiple disease states.

She has a BA in journalism from Seton Hall University. You can connect with Brooke on 

Articles

Insurer-pharmacy benefit manager (PBM) firms control most of the Medicare Part D market, steering patients to their pharmacies through network exclusions and targeted marketing. 

Insurer-PBM Firms Dominate Medicare Part D Market, Steering Patients to Their Pharmacies

Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.

She has a BA in English from Penn State University. You can connect with Maggie on 

Generalized myasthenia gravis (gMG) is an autoantibody-driven chronic disease for which there is no cure.


Understanding gMG: Autoantibodies and Life-Altering Muscle Weakness

Mutations in one of the first human-isolated strains of H5N1 bird flu in the US were identified by the Texas Biomedical Research Institute.

New Insights Into H5N1 Variability in Human Mutations

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial. 

FDA Approves Datopotamab Deruxtecan for HR-Positive/HER2-Negative Metastatic Breast Cancer

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

MASH

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Exploring Novel Treatment Options for Alopecia Areata

Video Series

Discussing the Pathophysiology of Alopecia Areata

Video content above is prompted by the following:

Describe the pathophysiology of alopecia areata (AA) and what makes it a chronic, autoimmune disease?.

a. Describe the role of inflammation in AA.

Videos

Panelists discuss how recent advancements, particularly the introduction of Janus kinase JAK inhibitors, are reshaping the treatment landscape for Aalopecia Aareata, offering new therapeutic options and addressing unmet needs in both efficacy and patient care.

Panelists discuss how alopecia areata (AA) is a chronic autoimmune disease characterized by inflammation that attacks hair follicles, leading to hair loss and varying disease progression.

Panelists discuss how concurrent comorbidities, such as thyroid disorders and other autoimmune conditions, are commonly seen in patients with alopecia areata (AA) and how they complicate disease management and increase the overall burden on patients.

Common Comorbidities Associated With Alopecia Areata

Panelists discuss how alopecia areata (AA) presents with hallmark symptoms such as sudden hair loss, and how the condition fluctuates over time, making it a relapsing or remitting inflammatory disease.

Hallmark Symptoms Seen With Alopecia Areata

Panelists discuss how ongoing or recurrent hair loss in patients with alopecia areata (AA) leads to significant psychological effects, impacting their mental health, and how different forms of AA may be harder for some patients to cope with, with strategies for managing these psychological challenges in clinical practice.

Psychosocial Impact of Alopecia Areata

Panelists discuss how alopecia areata (AA) is included in the differential diagnosis for hair loss conditions and how a definitive diagnosis is made through clinical evaluation and, when necessary, additional diagnostic tests.

Diagnosis of Alopecia Areata

Panelists discuss how managing alopecia areata (AA) involves multiple health care specialties, including dermatology and mental health, and how multidisciplinary care can be optimized, while also addressing strategies to alleviate financial barriers that patients may face in accessing treatment.

Multimodal Care for Patients With Alopecia Areata

Panelists discuss how the epidemiology of alopecia areata (AA) varies across different patient populations, with certain forms of the disease being more prevalent in specific groups.

Epidemiology Associated wWith Alopecia Areata

Panelists discuss how the decision to treat vs observe alopecia areata (AA) depends on factors such as disease severity, patient symptoms, and the use of scoring systems to guide treatment decisions.

Deciding When to Treat Patients With Alopecia Areata

Panelists discuss how key factors such as disease severity, patient preference, and payer requirements influence the choice of initial therapy for alopecia areata (AA), highlighting which drug classes have the highest and lowest success rates.

Choosing an Initial Therapy for Alopecia Areata

Alopecia areata (AA) is a chronic autoimmune disorder characterized by non-scarring hair loss, primarily due to the immune system's attack on hair follicles. The pathophysiology involves a breakdown in immune privilege of hair follicles, leading to an inflammatory response. Cytotoxic T cells, particularly CD8+ T cells, infiltrate the hair follicle, causing hair loss. Inflammation plays a crucial role, with cytokines such as IFN-γ and TNF-α contributing to the immune-mediated destruction of hair follicles. The chronic nature of AA is attributed to persistent immune dysregulation and genetic predisposition.

Discussing the Pathophysiology of Alopecia Areata

EP: 1.Discussing the Pathophysiology of Alopecia Areata

EP: 2.Common Comorbidities Associated With Alopecia Areata

EP: 3.Hallmark Symptoms Seen With Alopecia Areata

EP: 4.Psychosocial Impact of Alopecia Areata

EP: 5.Diagnosis of Alopecia Areata

EP: 6.Multimodal Care for Patients With Alopecia Areata

EP: 7.Epidemiology Associated wWith Alopecia Areata

EP: 8.Deciding When to Treat Patients With Alopecia Areata

EP: 9.Choosing an Initial Therapy for Alopecia Areata